Lunai Bioworks Inc. (NASDAQ:LNAI)
| Market Cap | 10.79M-85.2% |
| Revenue (ttm) | 20.94K |
| Net Income | -128.28M-26.8% |
| EPS | -61.25-8.3% |
| Shares Out | 4.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,039 |
| Open | 2.50 |
| Previous Close | 2.44 |
| Day's Range | 2.31 - 2.52 |
| 52-Week Range | 1.21 - 17.52 |
| Beta | 0.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 28, 2026 |
About LNAI
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
$LNAI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LNAI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LNAI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LNAI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LNAI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LNAI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LNAI
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $96.96K |
Estimated from each fund’s disclosed top holdings × AUM
LNAI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LNAI’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.